Key result
Drug-eluting balloons resulted in a numerically lower but statistically non-significant rate of major adverse cardiovascular events compared to drug-eluting stents in cancer patients with acute myocardial infarction (22.9% vs. 37.1%, HR 1.50, p=0.23).
Why the study?
Treatment for cancer patients presenting with AMI remains challenging, prompting an evaluation of the safety and efficiency of DEB versus DES in this high-risk group.
Does drug-eluting balloon reduce major adverse cardiovascular events compared to drug-eluting stent in cancer patients presenting with acute myocardial infarction?
Cohort (n=164)
No
Does drug-eluting balloon reduce major adverse cardiovascular events compared to drug-eluting stent in cancer patients presenting with acute myocardial infarction?
Hazard Ratio: 1.5 (95% CI 0.77–2.92)
Absolute Event Rate: 22.9% vs 37.1%
p-value: p=0.23
In cancer patients with AMI, drug-eluting balloons may offer a safer alternative to drug-eluting stents with a trend toward less major bleeding and comparable MACE rates.
May support drug-eluting balloon consideration in cancer patients with AMI; leaves open comparative MACE reduction versus stents.
BACKGROUND: Treatment for cancer patients presenting with acute myocardial infarction (AMI) remains challenging. The objective of the study was to investigate the safety and efficiency of drug eluting balloon (DEB) versus drug eluting stent (DES) in this high-risk group. METHODS: Between 1st January 2017 and 1st January 2022, cancer patients admitted to Beijing Chaoyang Hospital with AMI were retrospectively enrolled. The primary endpoint was major adverse cardiovascular event (MACE). The secondary endpoints included major bleeding events, heart failure and cardiac complications. RESULTS: A total of 164 cancer patients presenting with AMI were included in the final analysis. Patients treated with DEB had a numerically lower rate of MACE than those treated with DES during a median follow-up of 21.8 months (22.9% vs. 37.1%, p = 0.23). Patients treated with DEB had a trend towards lower rate of major bleeding events than patients treated with DES (6.3% vs. 18.1%, HR 2.96, 95% CI [0.88, 9.92], p = 0.08). There were no significant differences between the two groups with regards to the rate of heart failure (4.2% vs. 9.5%, p = 0.32) and cardiac complications (0.0% vs. 2.6%, p = 0.56). CONCLUSIONS: The present study demonstrated that in cancer patients with AMI, DEB had a trend towards lower rate of major bleeding events and a numerically lower rate of MACE compared with DES.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2023) conducted a cohort in Cancer with acute myocardial infarction (n=164). Drug-eluting balloon vs. Drug-eluting stent was evaluated on Major adverse cardiovascular event (MACE) (HR 1.50, 95% CI 0.77, 2.92, p=0.23). Drug-eluting balloons resulted in a numerically lower but statistically non-significant rate of major adverse cardiovascular events compared to drug-eluting stents in cancer patients with acute myocardial infarction (22.9% vs. 37.1%, HR 1.50, p=0.23).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: